Dr Ghia speaks with ecancer at EHA 23 about the design and early findings of the phase II CAPTIVATE study, treating CLL patients with ibrutinib and venetoclax.

He describes the sequencing of the two drugs, which are both approved as monotherapy, and assessments in place for depth of response.

Dr Ghia summarises some preliminary data, which indicate a good rate of response, and outlines when further results will be available.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.